Nanobiotix (NASDAQ:NBTX) Stock Price Down 14%

Nanobiotix S.A. (NASDAQ:NBTX)’s stock price dropped 14% during mid-day trading on Friday . The company traded as low as $4.60 and last traded at $4.60. Approximately 20,140 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 25,211 shares. The stock had previously closed at $5.35.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Friday, April 26th.

Nanobiotix Stock Performance

The stock has a 50-day moving average of $6.25 and a 200 day moving average of $6.62.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently raised its stake in Nanobiotix stock. Baillie Gifford & Co. increased its stake in shares of Nanobiotix S.A. (NASDAQ:NBTX) by 38.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,936,195 shares of the company’s stock after buying an additional 536,195 shares during the quarter. Baillie Gifford & Co. owned about 5.35% of Nanobiotix worth $16,942,000 at the end of the most recent reporting period. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.